For years, congressional Democrats have tried to pass legislation to allow Medicare to negotiate prescription drug prices for millions of beneficiaries.

Now, they believe they have a not-so-secret weapon: President Donald Trump.

On Wednesday, U.S. Reps. Elijah Cummings, D-Md., and Peter Welch, D-Vt., met privately for about an hour with Trump and newly appointed Health and Human Services Secretary Tom Price to discuss ways to combat high drug prices. They were joined by Johns Hopkins Hospital President Redonda Miller.

The congressmen pitched a House bill that would expand the federal government’s ability to negotiate drug prices, and they left feeling optimistic about what Trump will do.

“He made it clear to us that he wanted to do something,” Cummings said, characterizing Trump as “aware of the problem” and “enthusiastic.” Cummings is ranking member of the House Committee on Oversight and Government Reform.

Trump tweeted the day before the meeting with Cummings and Welch that he is “working on a new system where there will be competition” in the drug industry. After the meeting, Trump relayed his desire to work “in a bipartisan fashion to ensure prescription drug prices are more affordable for all Americans.”

I am working on a new system where there will be competition in the Drug Industry. Pricing for the American people will come way down! — Donald J. Trump (@realDonaldTrump) March 7, 2017

Allowing the federal government to negotiate drug prices is not a new idea, but Cummings and Welch painted a picture Wednesday of a political landscape that is ripe for change. They said they have a president who “gets it.”

And, Welch said, “the price is starting to kill us, we just can’t afford it.”

The lawmakers said they handed Trump and Price a bill to review and make comments. Cummings said he hopes to file the bill in two weeks.

A summary posted on the House committee website said the HHS secretary could negotiate lower prices with drug manufacturers under Medicare Part D, which provides coverage for prescription drugs bought at pharmacies.

An estimated 41 million Americans are covered by Part D. The drug benefit is provided through private insurers who each have their own formulary and generally use pharmacy benefit managers for drug purchasing. The latest proposal would direct the HHS secretary to establish a formulary, which is a list of allowed drugs.

The formulary would be used to “leverage” the purchasing power of the government, according to the summary.

Douglas Holtz-Eakin, a former director of the Congressional Budget Office and president of the American Action Forum, said the idea of lowering prices through Medicare Part D negotiations is “completely unrealistic.”

Holtz-Eakin pointed out that insurers are already used to managing health care for beneficiaries and there are formularies in those plans. Adding into the law that the HHS secretary should be part of the negotiations merely adds a “bully pulpit,” he said.

“The problem with the negotiation in Part D is not a political, partisan problem, it’s that it won’t work,” said Holtz-Eakin.

Trump himself, though, has long embraced the idea of Medicare negotiating drug prices. On the campaign trail in January 2016, he told a crowd in New Hampshire that Medicare could “save $300 billion” a year by getting discounts as the biggest buyer of prescription drugs, according to the Associated Press.

“We don’t do it. Why? Because of the drug companies,” Trump said.

PhRMA, the drug industry’s powerful lobbying group, says price negotiation is already happening.

“Large, powerful purchasers negotiate discounts and rebates directly with manufacturers, saving money for both beneficiaries and taxpayers,” PhRMA’s Holly Campbell stated in an email late Wednesday.

She pointed to a Congressional Budget Office report that said HHS would not be able to negotiate lower prices than already exist.

Trump met with pharmaceutical executives in January and told them “we have to get prices down for a lot of reasons, we have no choice.”

Umer Raffat, a research analyst at Evercore ISI, said the industry felt less jittery after that meeting. They walked away understanding that Trump wants to “promote innovation” while addressing prices.

This report is a cross-post from the Kaiser Health News website. KHN’s coverage of prescription drug development, costs and pricing is supported in part by the Laura and John Arnold Foundation.